Psychiatric Co-morbidity and Efficacy of Mirtazapine Treatment in Young Subjects With Chronic or Cyclic Vomiting Syndromes: A Case Series

Coskun M., Alyanak B.

JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, cilt.17, sa.3, ss.305-311, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 3
  • Basım Tarihi: 2011
  • Doi Numarası: 10.5056/jnm.2011.17.3.305
  • Dergi Adı: JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.305-311
  • Anahtar Kelimeler: Anxiety, Child, Familial cyclic vomiting syndrome, Gastrointestinal diseases, Mirtazapine, FUNCTIONAL GASTROINTESTINAL DISORDERS, EFFECTIVE PROPHYLACTIC THERAPY, HEALTH-CARE SEEKING, OPEN-LABEL, CHILDREN, NAUSEA, ADOLESCENTS, SYMPTOMS, EPIDEMIOLOGY, DEPRESSION
  • İstanbul Üniversitesi Adresli: Evet

Özet

The aim of this case report was to evaluate the psychiatric co-morbidity and efficacy of mirtazapine treatment in young subjects with chronic or cyclic vomiting syndromes. This is a case series of 8 young subjects (age range of 6-16 years, 11.12 +/- 3.52 years) who were referred or consulted to child psychiatry department. They were referred or consulted by pediatric gastroenterology or surgery departments for the presence of non-remitting and medically unexplained vomiting. They were investigated for co-morbid psychiatric disorders using a structured psychiatric interview. An open trial of mirtazapine was conducted for the treatment and/or prevention of vomiting. Primary outcome measure was Clinical Global Impression-Improvement scale. Subjects were diagnosed with chronic (n = 5) or cyclic (n = 3) vomiting syndromes. Duration of vomiting ranged from 6 months to 10 years (3.5 +/- 3.2 years). All subjects received multiple psychiatric diagnoses with anxiety disorders being the most frequent. Maximum mirtazapine dosage was 7.5-30 mg/day (16.00 +/- 6.16 mg/day). Three subjects showed complete remission and 5 subjects showed much to very much improvement in vomiting. Most frequent side effects were increased appetite, weight gain and sedation. Young subjects with chronic or cyclic vomiting may frequently suffer anxiety and/or depressive symptoms or disorders. Mirtazapine could be an effective treatment option for the treatment of vomiting and co-morbid anxiety or depressive disorders in these subjects. More systematic research are needed on this topic.